Biotechnology
Price
$654.27
+4.73%Market Cap
$68.59B
Day High
$654.93
Day Low
$625.70
Regeneron delivered strong Q1 2026 revenue growth of 19.0% YoY to $3.61B, driven by robust product demand, but net income declined 10.1% to $727.2M as R&D spending surged 16.3% and current liabilities jumped 43.2%.
Key risk: R&D Expense Escalation Threatening Profitability
R&D expenses reached $1,543.5M in Q1 2026, up 16.3% YoY and representing ~42.8% of revenue. If pipeline programs fail to generate returns, this level of spending could materially erode margins and earnings over time.
Other Biotechnology companies